Onco-Innovations Advances Lead Oncology Candidate ONC010 Toward Clinical Studies

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells' DNA repair mechanisms and potentially address treatment resistance. The company recently achieved a milestone by advancing kilogram-scale manufacturing of a key precursor used to produce ONC010's active pharmaceutical ingredient, a critical step toward future formulation development, GMP production, and clinical studies. This manufacturing progress is essential for generating the supply needed for preclinical toxicity studies and eventual first-in-human trials.

In parallel, Onco-Innovations signed a letter of intent with Nanosoft Polymers to collaborate on polymer development, drug delivery optimization, and formulation work. This partnership aims to enhance the delivery and efficacy of ONC010, leveraging Nanosoft's expertise in polymer-based drug delivery systems. Additionally, the company has engaged Nucro-Technics for bioanalytical development and Avance Clinical for clinical and regulatory planning. These collaborations are part of a broader strategy to build the manufacturing, formulation, and clinical infrastructure necessary to advance ONC010 toward clinical trials.

The significance of these developments lies in the potential of ONC010 to overcome treatment resistance in solid tumors. By inhibiting PNKP, an enzyme involved in DNA repair, ONC010 may sensitize cancer cells to DNA-damaging agents, offering a new therapeutic option for patients with resistant cancers. The company's progress in scaling up production and securing partnerships reflects its commitment to moving this candidate through the development pipeline.

Onco-Innovations is a Canadian-based company focused on cancer research and treatment, with an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit the company's website at https://oncoinnovations.com/. The latest news and updates regarding ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.